---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125386"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:06:10.029295+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ORIC Q3 cash $282.4M, R&D up 39% YoY; ORIC-114 and ORIC-944 on track

## Summary
- Cash and investments of $282.4M as of Sep 30, 2024, expected to fund operations into late 2026.
- R&D expenses $31.2M for Q3 2024 vs $22.4M in Q3 2023, increase of $8.8M (39%).
- Presented preclinical data supporting best-in-class potential for ORIC-114 in EGFR exon 20 insertion NSCLC; Phase 1b data expected H1 2025.
- Entered clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson for ORIC-944 in prostate cancer.
- Appointed Keith Lui as SVP of Commercial and Medical Affairs.

## SEC filing metadata
- accession: 0000950170-24-125386
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017024125386/0000950170-24-125386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017024125386/oric-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125386
- JSON: https://secwatch.observer/filing/0000950170-24-125386.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.